Instrument NameAstrazeneca Plc ADRInstrument Symbol(AZN-Q)

Instrument ExchangeNASDAQ

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

Cancer, a complex disease characterized by uncontrolled cell growth and proliferation, is often rooted in defects within DNA repair mechanisms. Normally, cells possess intricate repair pathways that rectify mutations or damage caused by environmental factors or internal processes. However, when these pathways malfunction, either due to genetics or acquired mutations,...

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential to shorten drug development timelines...

The urgent need for innovative technologies to accelerate the development of life-saving cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential to shorten drug development timelines is paramount. DNA-damage response (DDR)-based therapies, which target cancer cells' repair mechanisms, are emerging...

/CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new...

Shares of AstraZeneca (AZN) are down 5% after the British pharmaceutical company reported disappointing ...

These stocks are all up more than 20% this year.

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma market will be worth $39B in sales by 2032.

The winners of today might not compete in the lucrative new segment of tomorrow.

These stocks arguably deserve more respect from investors.

The British drugmaker's Q2 results were good, but seemingly not good enough for many investors.

AZN earnings call for the period ending June 30, 2024.

Second-quarter profit was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said

The big pharma company's top drug is losing ground, but its dividend keeps rising.

Analysts expect this small-cap biotech stock to more than double in value as it integrates AI into its drug development process.

You won't need much money to start investing in these great stocks.

/CNW/ -- USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care for a large number of patients.

There's probably a big enough pie here for everyone to get a slice.

Now is the time to invest in these great stocks.

AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.

Both businesses have road maps for the future, but one is better.

Its new strategic roadmap aims to catapult the company forward.